Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1.35 NOK
Change Today +0.06 / 4.65%
Volume 2.0M
NEL On Other Exchanges
Symbol
Exchange
Berlin
As of 10:25 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

nel asa (NEL) Snapshot

Open
1.30 NOK
Previous Close
1.29 NOK
Day High
1.40 NOK
Day Low
1.29 NOK
52 Week High
11/24/14 - 1.80 NOK
52 Week Low
10/23/14 - 0.61 NOK
Market Cap
538.6M
Average Volume 10 Days
1.5M
EPS TTM
-0.0078 NOK
Shares Outstanding
398.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEL ASA (NEL)

Related News

No related news articles were found.

nel asa (NEL) Related Businessweek News

No Related Businessweek News Found

nel asa (NEL) Details

DiaGenic ASA researches, develops, sells, and markets blood based gene expression tests. The company was founded in 1998 and is headquartered in Oslo, Norway.

Founded in 1998

nel asa (NEL) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: 1.2M NOK
Compensation as of Fiscal Year 2013.

nel asa (NEL) Key Developments

DiaGenic ASA Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

DiaGenic ASA announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total operating revenues of NOK 12,067,000 compared with NOK 22,000 for the same period a year ago. Operating loss was NOK 7,064,000 compared with NOK 6,804,000 for the same period a year ago. Loss before tax was NOK 6,137,000 compared with NOK 6,703,000 for the same period a year ago. Net loss was NOK 1,010,000 or NOK 0.00 per basic and diluted share compared with NOK 6,703,000 or NOK 0.95 per basic and diluted share for the same period a year ago. Net cash provided by operating activities was NOK 14,501,000 compared with net cash used in operating activities of NOK 6,215,000 for the same period a year ago. Acquisitions of fixed assets was NOK 32,998,000. For the quarter, the company reported total operating revenues of NOK 12,067,000 compared with NOK 157,000 for the same period a year ago. Operating loss was NOK 13,173,000 compared with NOK 37,185,000 for the same period a year ago. Loss before tax was NOK 11,633,000 compared with NOK 36,633,000 for the same period a year ago. Net loss was NOK 6,506,000 or NOK 0.02 per basic and diluted share compared with NOK 36,633,000 or NOK 5.66 per basic and diluted share for the same period a year ago. Net cash provided by operating activities was NOK 5,498,000 compared with net cash used in operating activities of NOK 35,493,000 for the same period a year ago. Acquisitions of fixed assets was NOK 32,998,000. Acquisitions of fixed assets was NOK,000 compared with NOK,000 for the same period a year ago.

NEL ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

NEL ASA reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total operating revenue of NOK 12.067 million against NOK 0.022 million a year ago. Operating loss was NOK 7.064 million against NOK 6.804 million a year ago. Pre-tax loss was NOK 6.137 million against NOK 6.703 million a year ago. Net loss was NOK 1.010 million against NOK 6.703 million or NOK 0.95 net loss per share after dilution a year ago. Net cash flow from operating activities was NOK 14.501 million against net cash used in operating activities of NOK 6.215 million a year ago. Acquisitions of fixed assets was NOK 32.998 million. For the year, the company reported total operating revenue of NOK 12.067 million against NOK 0.157 million a year ago. Operating loss was NOK 13.173 million against NOK 37.185 million a year ago. Pre-tax loss was NOK 11.633 million against NOK 36.633 million a year ago. Net loss was NOK 6.506 million or NOK 0.02 net loss per share after dilution against NOK 36.633 million or NOK 5.66 net loss per share after dilution a year ago. Net cash flow from operating activities was NOK 5.498 million against net cash used in operating activities of NOK 35.493 million a year ago. Acquisitions of fixed assets was NOK 32.998 million.

DiaGenic ASA to Report Q1, 2015 Results on Apr 30, 2015

DiaGenic ASA announced that they will report Q1, 2015 results on Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEL:NO 1.35 NOK +0.06

NEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DiaxonHit €0.57 EUR -0.01
View Industry Companies
 

Industry Analysis

NEL

Industry Average

Valuation NEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 120.1x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEL ASA, please visit www.diagenic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.